4'-phosphopantothenate (P-Pa)

4'-phosphopantothenate is a critical metabolic intermediate in the universal five-step biosynthetic pathway of Coenzyme A (CoA), a vital cofactor for energy metabolism, fatty acid synthesis, and the citric acid cycle [1, 4]. It is synthesized from pantothenate (vitamin B5) by the enzyme pantothenate kinase (PANK) and is subsequently converted into 4'-phosphopantothenoylcysteine by phosphopantothenoylcysteine synthetase (PPCS) [1, 8]. In humans, mutations in the PANK2 gene lead to Pantothenate Kinase-Associated Neurodegeneration (PKAN), a rare and severe neurodegenerative disorder characterized by CoA deficiency and brain iron accumulation [1, 6]. Because 4'-phosphopantothenate is the product of the PANK2 enzyme, therapeutic strategies for PKAN often involve bypassing the metabolic block by providing this intermediate or its derivatives [7, 10]. For example, the prodrug fosmetpantotenate (RE-024) was developed to deliver 4'-phosphopantothenate directly into cells to restore intracellular CoA levels [7]. Although it is a metabolite rather than a protein target, its role as a critical bottleneck in CoA synthesis makes it a central focus for pharmacological intervention and biomarker monitoring in metabolic and neurodegenerative diseases [1, 17].

Other names

Phosphopantothenic acid4'-phosphopantothenic acidD-4'-phosphopantothenatePantothenate 4'-phosphate4-PPA

Drugs targeting this pathway primarily act as prodrugs to deliver the molecule directly to cells or as allosteric activators of pantothenate kinase to increase its endogenous production, thereby bypassing metabolic blocks in Coenzyme A biosynthesis.